Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949211 | 0.96 | HTR6 (0.47) | HTR6CYP19A1ALOX5ALKUSP30 | |
| SCHEMBL2030083 | 0.91 | HTR6 (0.49) | HTR6CYP19A1ALOX5ALKCYP3A4 | |
| SCHEMBL10187155 | 0.78 | HTR6 (0.56) | HTR6CYP19A1ALKCYP3A4CYP2D6 | |
| SCHEMBL31295102 | 0.78 | HTR6 (0.53) | HTR6ALOX5ALK | |
| Hydrochloric Acid SCHEMBL9948705 | 0.77 | HTR6 (0.55) | HTR6CYP19A1ALKCYP3A4CYP2D6 | |
| SCHEMBL2131067 | 0.77 | HTR6 (0.49) | HTR6CYP19A1ALOX5ALKCYP3A4 | |
| SCHEMBL2027090 | 0.77 | HTR6 (0.46) | HTR6CYP19A1ALOX5ALK | |
| SCHEMBL9948692 | 0.75 | HCRTR1 (0.51) | HTR6CYP19A1ALKCYP3A4CYP2D6 | |
| SCHEMBL2023408 | 0.75 | HTR6 (0.56) | HTR6CYP19A1ALKCYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9949887 | 0.73 | HTR6 (0.53) | HTR6CYP19A1ALKCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | HTR6 1928/4885CYP19A1 1037/4885ALOX5 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.